RT Journal Article
SR Electronic
T1 Medial temporal lobe hyperconnectivity is key to Alzheimer’s disease: Insight from physiological aging to dementia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.11.23.23298948
DO 10.1101/2023.11.23.23298948
A1 Chauveau, Léa
A1 Landeau, Brigitte
A1 Dautricourt, Sophie
A1 Turpin, Anne-Laure
A1 Delarue, Marion
A1 Hébert, Oriane
A1 de La Sayette, Vincent
A1 Chételat, Gaël
A1 de Flores, Robin
YR 2023
UL http://medrxiv.org/content/early/2023/11/23/2023.11.23.23298948.abstract
AB Curing Alzheimer’s disease (AD) remains hampered by an incomplete understanding of its pathophysiology and progression. Dysfunction within medial temporal lobe networks may provide key insights, as AD proteins seem to propagate specifically through the anterior-temporal (AT) and posterior-medial (PM) systems. Using monocentric longitudinal data from 267 participants spanning physiological aging to the full AD continuum, we found that advancing age was associated with decreased PM connectivity and increased AT connectivity over adult life. When specifically assessing AD-relevant connectivity changes, all AD-associated clinicopathological features, including elevated amyloid burden, AD-typical glucose hypometabolism, hippocampal atrophy, greater cognitive impairment and faster progression from MCI to AD-dementia, were consistently linked to AT hyperconnectivity in healthy to AD-demented older adults. Our comprehensive approach allowed us to reveal that excessive connectivity within the AT network is a pivotal mechanism catalysing pathological process and progression of AD. Such findings hold promise for early diagnosis and therapeutic strategies targeting these specific network alterations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Programme Hospitalier de Recherche Clinique (PHRCN 2011 A01493 38 and PHRCN 2012 12 006 0347), Agence Nationale de la Recherche (ANR LONGVIE 2007), Fondation Plan Alzheimer (Alzheimer Plan 2008–2012), Association France Alzheimer et maladies apparentées AAP 2013, Région Basse Normandie, and Institut National de la Santé et de la Recherche Médicale (INSERM).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Protection des Personnes Nord-Ouest III of CHU Caen Normandie gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesDataset used in the present study is available from G.C. upon reasonable request, for the purpose of replicating procedures and results.